Equity Research

William Blair Analyst Raju Prasad Comments on Bluebird Bio in Reuters

The FDA recently ruled bluebird bio’s blood disorder therapy as effective, and William Blair analyst Raju Prasad is quoted on the implications for the company.

Read the full story

Our Latest News

Thursday, May 8, 2025

The Right Platform for This Moment

Amid the evolving economic landscape of the past few years and continued shifts in 2025, we at William Blair have worked hard to expand our platform and provide creative solutions.
Watch the video
Tuesday, May 6, 2025

Cash is Still King, Especially During the Great Iberian Blackout (El Apagón)

The complete power outage across the Iberian Peninsula last week was a wake-up call. William Blair’s Richard de Chazal outlines five lessons to take away from the event.
Read more
Monday, May 5, 2025

Roper Technologies, Inc.: Initiation of Research Coverage

William Blair initiated research coverage of Roper Technologies, Inc. (ROP $557.59), a leading operator and acquirer of high-quality vertical software assets across multiple industries.
Read more

See more news

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures

William Blair Thinking

William Blair Thinking Podcast

William Blair Thinking

William Blair Analyst Raju Prasad Comments on Bluebird Bio in Reuters

Our Latest News

The Right Platform for This Moment

Cash is Still King, Especially During the Great Iberian Blackout (El Apagón)

Roper Technologies, Inc.: Initiation of Research Coverage

Are you sure you want to leave?